Chris Moore

This study shows that CD19 CAR-engineered regulatory T cells reduce B cell numbers, inflammation, and autoantibodies in lupus models, promoting long-term immune tolerance.

This study links oncogenic RAS activity to immune priming and adenosine-driven immune evasion in lung adenocarcinoma, showing both pro-immunogenic and immunosuppressive effects.

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.